Progress of research on TRAIL and its receptors in kidney diseases

doi:10.3877/cma.j.issn.2095-3216.2015.04.009

Abstract

Abstract:

TNF-related apoptosis-inducing ligand (TRAIL) is an important pro-apoptotic cytokine belonging to the TNF superfamily. TRAIL has its pro-apoptosis effect by binding to death receptors (DR), which is regulated by decoy receptors (DcR) leading to anti-apoptosis and promoting proliferation functions, etc. TRAIL combines with different receptors triggering various pathological actions so as to participate in the progression of kidney diseases including diabetic nephropathy, and is closely related to the prognosis of the kidney diseases. This review will describe the structures and functions of TRAIL as well as its receptors, and will introduce their roles in kidney diseases.

Key words: TNF-related apoptosis-inducing ligand (TRAIL), Receptor, Kidney diseases

Jia Chen, Yani He. Progress of research on TRAIL and its receptors in kidney diseases[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2015, 04(04): 208-211.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2015.04.009

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2015/V04/I04/208

References 27

[1]	Candido R. The osteoprotegerin/tumor necrosis factor-related apoptosis-inducing ligand axis in the kidney [J]. Curr Opin Nephrol Hypertens, 2014, 23(1): 69-74.
[2]	Azijli K, Weyhenmeyer B, Peters GJ, et al. Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family [J]. Cell Death Differ, 2013, 20(7): 858-868.
[3]	Lorz C, Benito A, Ucero AC, et al. Trail and kidney disease [J]. Front Biosci, 2009, 14: 3740-3749.
[4]	Duiker EW, Mom CH, de Jong S, et al. The clinical trail of TRAIL [J]. Eur J Cancer, 2006, 42(14): 2233-2240.
[5]	Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors [J]. Cell Res, 2004, 14(5): 359-372.
[6]	Vindrieux D, Reveiller M, Chantepie J, et al. Down-regulation of DcR2 sensitizes androgen dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis [J]. Cancer Cell Int, 2011, 11: 42.
[7]	Lalaoui N, Morle A, Merino D, et al. TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT [J]. PloS One, 2011，6: e19679.
[8]	Sagiv A, Biran A, Yon M, et al. Granule exocytosis mediates immune surveillance of senescent cells [J]. Oncogene, 2013, 32(15): 1971-1977.
[9]	Lorz C, Benito-Martin A, Boucherot A, et al. The death ligand TRAIL in diabetic nephropathy [J]. J Am Soc Nephrol, 2008，19(5)：904-1014.
[10]	Voelkel-Johnson C. TRAIL-mediated signaling in prostate, bladder and renal cancer [J]. Nat Rev Urol, 2011, 8(8): 417-427.
[11]	Spierings DC, de Vries EG, Vellenga E, et al. Tissue distribution of the death ligand TRAIL and its receptors [J]. J Histochem Cytochem, 2004, 52(6): 821-831.
[12]	Liu X, Yue P, Khuri FR，et al. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity [J]. Cancer Res, 2005, 65(20): 9169-9175.
[13]	Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours [J]. Nature, 2005, 436(7051): 642.
[14]	Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas [J]. Nature, 2007, 445(7128): 656-660.
[15]	Chang YH, Lin KD, He SR, et al. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy [J]. Metabolism, 2011, 60(8): 1064-1069.
[16]	Sanchez-Nino MD, Benito-Martin A, Ortiz A. New paradigms in cell death in human diabetic nephropathy [J]. Kidney Int, 2010, 78(8): 737-744.
[17]	Bernardi S, Norcio A, Toffoli B，et al. Potential role of TRAIL in the management of autoimmune diabetes mellitus [J]. Curr Pharm Des, 2012, 18(35): 5759-5765.
[18]	Bernardi S, Zauli G, Tikellis C, et al. TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation [J]. Clin Sci, 2012, 123(9): 547-555.
[19]	Gordin D, Soro-Paavonen A, Thomas MC, et al. Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes. Diabetes Care, 2013, 36(7): 1827-1833.
[20]	Xu SQ, El-Deiry WS. p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4 [J]. Biochem Biophys Res Commun, 2000, 269(1): 179-190.
[21]	Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney [J]. Am J Physiol Regul Integr Comp Physiol, 2011, 300(5): R1009-R1022.
[22]	Zauli G, Toffoli B, di Iasio MG, et al. Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes, 2010, 59(5): 1261-1265.
[23]	Nguyen V, Cudrici C, Zernetkina V, et al. TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects [J]. Clin Immunol, 2009, 132(1): 32-42.
[24]	El-Shehaby A, Darweesh H, El-Khatib M, et al. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis [J]. J Clin Immunol, 2011, 31(5): 848-856.
[25]	Song CJ, Liu XS, Zhu Y, et al. Expression of TRAIL, DR4, and DR5 in kidney and serum from patients receiving renal transplantation [J]. Transplant Proc, 2004, 36(5): 1340-1343.
[26]	Svensson M, Dahle DO, Mjoen G, et al. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study [J]. Nephrol Dial Transplant, 2012, 27(6): 2571-2575.
[27]	Liabeuf S, Barreto DV, Barreto FC, et al. The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients [J]. Nephrol Dial Transplant, 2010, 25(8): 2596-2602.

Please choose a citation manager

Content to export